Acrivon Therapeutics(us:ACRV)
1.68
-17.24%
Updated on 2025-04-02
Open:1.99
Close:1.68
High:1.99
Low:1.56
Prev Close:2.03
Volume:569931.00
Turnover:1.01M
Turnover Ratio:1.82%
Shares:31.35M
MarketCap:52.67M
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 1 | 23 | 0.00% | 0 | 1 | 0 |
| 2024-03-31 | 52 | 15244538 | 67.34% | 11 | 14 | 14 |
| 2023-12-31 | 45 | 15295876 | 67.91% | 2 | 16 | 13 |
| 2023-09-30 | 44 | 15093861 | 68.28% | 4 | 15 | 13 |
| 2023-06-30 | 43 | 15126531 | 68.54% | 5 | 17 | 14 |
| 2023-03-31 | 38 | 15208778 | 69.38% | 22 | 6 | 6 |
| 2022-12-31 | 18 | 14965637 | 68.27% | 18 | 0 | 0 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-03-31 | Ra Capital Management, L.P. | 4810508 | 21.25% | 0 | |
| 2024-03-31 | Perceptive Advisors Llc | 3007858 | 13.29% | 0 | |
| 2024-03-31 | Citadel Advisors Llc | 1680027 | 7.42% | 30368 | 1.84% |
| 2024-03-31 | Sands Capital Ventures, Llc | 1652605 | 7.30% | 0 | |
| 2024-03-31 | Wellington Management Group Llp | 888130 | 3.92% | 0 | |
| 2024-03-31 | Blackrock Inc. | 743901 | 3.29% | 178069 | 31.47% |
| 2024-03-31 | Marshall Wace, Llp | 597469 | 2.64% | 0 | |
| 2024-03-31 | Vanguard Group Inc | 507185 | 2.24% | 31208 | 6.56% |
| 2024-03-31 | Geode Capital Management, Llc | 242846 | 1.07% | 53646 | 28.35% |
| 2024-03-31 | State Street Corp | 133276 | 0.59% | 0 |
About
Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.
Address:480 Arsenal Way,Suite 100
Website:http://acrivon.com
Market Movers